Publications by authors named "Per S Soerensen"
Article Synopsis
- Natalizumab outperforms fingolimod in reducing relapses in patients with relapsing-remitting multiple sclerosis (RRMS), but it's unclear if this holds true for all demographic groups.
- The study aimed to assess the effectiveness of these treatments across different patient subgroups, considering factors like age, sex, disease duration, and disability status.
- Results showed that natalizumab led to fewer relapses and a higher chance of improving disability in various subgroups, indicating its potential superiority, particularly in younger patients and those with less severe disease.
